Amanda E D Van Swearingen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4448700/publications.pdf

Version: 2024-02-01

47	852	516561	501076
papers	citations	16 h-index	28 g-index

50	50	50	1775
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	<scp>HER2â€positive</scp> breast cancer brain metastasis: A new and exciting landscape. Cancer Reports, 2022, 5, e1274.	0.6	54
2	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
3	Brain metastasis as first and only metastatic relapse site portends poor outcomes in patients with advanced HER2+ breast cancer.. Journal of Clinical Oncology, 2022, 40, 1045-1045.	0.8	1
4	Preparation and Characterization of Poly(2-oxazoline) Micelles for the Solubilization and Delivery of Water Insoluble Drugs. Bio-protocol, 2021, 11, e3959.	0.2	3
5	Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic Agents. Bio-protocol, 2021, 11, e3953.	0.2	0
6	Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacology and Translational Science, 2021, 4, 703-712.	2.5	7
7	Abstract PD15-01: Snord67 promotes lymph node metastasis through U6-mediated alternative splicing in breast cancer. , 2021, , .		0
8	Effect of type and timing of systemic therapy on risk of radiation necrosis in patients with HER2+ breast cancer brain metastases.. Journal of Clinical Oncology, 2021, 39, e14002-e14002.	0.8	0
9	Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).. Journal of Clinical Oncology, 2021, 39, 1041-1041.	0.8	0
10	An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).. Journal of Clinical Oncology, 2021, 39, 9521-9521.	0.8	0
11	OTHR-10. Diverse survival outcomes of HER2+ Breast Cancer Brain Metastases (BrCBM) presenting with isolated brain relapse compared to those with concurrent extracranial disease. Neuro-Oncology Advances, 2021, 3, iii16-iii16.	0.4	0
12	OTHR-14. An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM). Neuro-Oncology Advances, 2021, 3, iii17-iii17.	0.4	0
13	Advances in the management of breast cancer brain metastases. Neuro-Oncology Advances, 2021, 3, v63-v74.	0.4	10
14	A Need for More Molecular Profiling in Brain Metastases. Frontiers in Oncology, 2021, 11, 785064.	1.3	1
15	52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES. Neuro-Oncology Advances, 2020, 2, ii10-ii11.	0.4	0
16	A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. Cancer Research, 2020, 80, 4972-4985.	0.4	23
17	Receptor discordance in breast cancer brain metastases: when knowledge is power. Neuro-Oncology, 2020, 22, 1060-1061.	0.6	3
18	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Research, 2020, 80, 4314-4323.	0.4	51

#	Article	IF	Citations
19	High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. Science Advances, 2020, 6, eaba5542.	4.7	48
20	Abstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA. , 2020, , .		0
21	258â€…Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2020, , .		0
22	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. Neuro-Oncology Advances, 2019, 1, vdz005.	0.4	9
23	Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. Nature Communications, 2019, 10, 4192.	5.8	52
24	The Promise of Immunotherapy for Breast Cancer Brain Metastases. Current Breast Cancer Reports, 2019, 11, 241-247.	0.5	7
25	Experimentally Dissecting the Origins of Peroxiredoxin Catalysis. Antioxidants and Redox Signaling, 2018, 28, 521-536.	2.5	25
26	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Research and Treatment, 2018, 171, 637-648.	1.1	40
27	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. Journal of Clinical Investigation, 2018, 128, 1371-1383.	3.9	126
28	Abstract 2813: Efficacy and pharmacokinetics of niraparib in BRCA-mutant and wild-type intracranial triple negative breast cancer murine models. Cancer Research, 2018, 78, 2813-2813.	0.4	1
29	Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro-Oncology, 2017, 19, 1481-1493.	0.6	32
30	Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-Oncology, 2017, 19, 1469-1480.	0.6	42
31	Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models. , 2017, , .		0
32	Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT^{Â®} nanoparticle formulation against non-small-cell lung cancer brain metastases. Nanomedicine, 2016, 11, 1947-1955.	1.7	23
33	Abstract 3867: Combined PI3K and AURKA inhibition are efficacious in triple-negative breast cancer models. , 2016, , .		0
34	Multidisciplinary Management of Breast Cancer Brain Metastases. Oncology, 2016, 30, 923-33.	0.4	8
35	Simplified dietary acute tryptophan depletion: effects of a novel amino acid mixture on the neurochemistry of C57BL/6J mice. Food and Nutrition Research, 2015, 59, 27424.	1.2	11
36	Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCAâ€“Wild-Type Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 920-930.	1.9	62

#	Article	IF	Citations
37	Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models. , 2015, , .		1
38	Dietary manipulation of serotonergic and dopaminergic function in C57BL/6J mice with amino acid depletion mixtures. Journal of Neural Transmission, 2014, 121, 153-162.	1.4	16
39	Breast cancer brain metastases: evidence for neuronal-like adaptation in a â€˜breast-to-brainâ€™ transition?. Breast Cancer Research, 2014, 16, 304.	2.2	13
40	Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models. , 2014, , .		1
41	Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis. Oncology, 2014, 28, 579, 584-5.	0.4	1
42	Sex differences in novelty- and psychostimulant-induced behaviors of C57BL/6 mice. Psychopharmacology, 2013, 225, 707-718.	1.5	56
43	Estradiol replacement enhances cocaine-stimulated locomotion in female C57BL/6 mice through estrogen receptor alpha. Neuropharmacology, 2013, 72, 236-249.	2.0	17
44	Specific Residues in Peroxiredoxins Promote Peroxide Reactivity Through Effects on Cysteine pKa, Transition State Stabilization and Oligomerization. Free Radical Biology and Medicine, 2012, 53, S151.	1.3	0
45	Individual differences in psychostimulant responses of female rats are associated with ovarian hormones and dopamine neuroanatomy. Neuropharmacology, 2012, 62, 2267-2277.	2.0	24
46	Effects of Acute Tryptophan Depletion on Brain Serotonin Function and Concentrations of Dopamine and Norepinephrine in C57BL/6J and BALB/cJ Mice. PLoS ONE, 2012, 7, e35916.	1.1	69
47	Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery. Frontiers in Oncology, 0, 12, .	1.3	4